Literature DB >> 9399661

Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families.

Q Wang1, F Desseigne, C Lasset, J C Saurin, C Navarro, T Yagci, I Keser, H Bagci, G Luleci, T Gelen, J A Chayvialle, A Puisieux, M Ozturk.   

Abstract

Hereditary non-polyposis colon cancer (HNPCC) is a common hereditary disease characterized by a predisposition to an early onset of colorectal cancer. The majority of the HNPCC families carry germline mutations of either hMSH2 or hMLH1 genes, whereas germline mutations of hPMS1 and hPMS2 genes have rarely been observed. Almost all of the germline mutations reported so far concern typical HNPCC families. However, there are families that display aggregations of colon cancer even though they do not fulfil all HNPCC criteria (incomplete HNPCC families) as well as sporadic cases of early onset colon cancers that could be related to germline mutations of these genes. Therefore, we screened germline mutations of hMSH2 and hMLH1 genes in 3 groups of patients from France and Turkey: typical HNPCC (n = 3), incomplete HNPCC (n = 9) and young patients without apparent familial history (n = 7). By in vitro synthesis of protein assay, heteroduplex analysis and direct genomic sequencing, we identified 1 family with hMSH2 mutation and 5 families with hMLH1 mutations. Two of the 3 HNPCC families (66%) displayed hMLH1 germline mutations. Interestingly, 4 of 9 families with incomplete HNPCC (44%) also displayed mutations of hMSH2 or hMLH1 genes. In contrast, no germline mutation of these genes was found in 7 young patients. Our results show that germline mutations of hMSH2 and hMLH1 genes contribute to a significant fraction of familial predisposition to colon cancer cases that do not fulfil all diagnostic criteria of HNPCC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399661     DOI: 10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome.

Authors:  Michael P Farrell; David J Hughes; Ian R Berry; David J Gallagher; Emily A Glogowski; Stewart J Payne; Michael J Kennedy; Róisín M Clarke; Susan A White; Cian B Muldoon; Fiona Macdonald; Pauline Rehal; Danielle Crompton; Solvig Roring; Sarah T Duke; Trudi McDevitt; David E Barton; Shirley V Hodgson; Andrew J Green; Peter A Daly
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

2.  Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis.

Authors:  M P de Leon; M Pedroni; P Benatti; A Percesepe; C Di Gregorio; M Foroni; G Rossi; M Genuardi; G Neri; F Leonardi; A Viel; E Capozzi; M Boiocchi; L Roncucci
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

3.  Analysis of mismatch repair gene mutations in Turkish HNPCC patients.

Authors:  Berrin Tunca; Monica Pedroni; Gulsah Cecener; Unal Egeli; Enrica Borsi; Abdullah Zorluoglu; Carmela Di Gregorio; Tuncay Yilmazlar; Omer Yerci; Maurizio Ponz de Leon
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

4.  High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome.

Authors:  Christine Nyiraneza; Etienne Marbaix; Mireille Smets; Christine Galant; Christine Sempoux; Karin Dahan
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  Extensive molecular screening for hereditary non-polyposis colorectal cancer.

Authors:  B Dieumegard; S Grandjouan; J C Sabourin; M L Le Bihan; I Lefrère; J P Pignon; P Rougier; P Lasser; J Bénard; D Couturier; B Bressac-de Paillerets
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.